Health - Monday, April 13, 2026

FDA officials said an internal analysis found results were not submitted for nearly 30% of studies “highly likely” to fall under mandatory reporting requirements.

New research is upending what we thought about the consciousness of patients, leaving families with agonizing choices.

HaloMD is a middleman that became the top filer of out-of-network billing disputes on behalf of medical providers.

CMS greenlights more than 150 digital health companies for its ACCESS experiment, a new program for tech-backed chronic care with outcome-aligned payments.

Scientists have developed a new way to fight gum disease without wiping out the mouth’s helpful bacteria—a major shift from traditional treatments. Instead of killing everything, this targeted approach blocks only the harmful microbes that drive periodontitis, allowing beneficial bacteria to thrive and restore balance naturally.

New research reveals that obesity affects men and women in surprisingly different ways. Men are more likely to develop harmful abdominal fat and signs of liver stress, while women show higher inflammation and cholesterol levels. These differences could help explain why health risks vary between sexes. Scientists say this could lead to more tailored treatments for obesity.

President Trump vowed to take on health insurers, but his policies tell a different story.

Revolution Medicines 'unprecedented' cancer trial data, Allogene's off-the-shelf CAR-T, and other biotech news

For years, scientists believed our lifespan was mostly shaped by environment and chance, with genetics playing only a minor role. But a new study from the Weizmann Institute flips that idea on its head, revealing that genes may actually account for about half of the differences in how long people live. By analyzing massive twin datasets—including twins raised apart—and using innovative simulations to filter out deaths from accidents and other external causes, researchers uncovered a hidden genetic influence that had been masked for decades.

A twice-yearly injection may soon change how high blood pressure is treated. In a global trial, patients receiving the experimental drug zilebesiran alongside standard therapy saw greater blood pressure reductions than those on standard treatment alone. The drug works by blocking a key liver protein, helping blood vessels relax. Researchers say this long-lasting approach could make it much easier for patients to keep their condition under control.